Alembic Pharmaceuticals Limited (NSE:APLLTD)
India · Delayed Price · Currency is INR | Market Cap | 178.32B |
| Revenue (ttm) | 70.83B |
| Net Income (ttm) | 6.34B |
| Shares Out | 196.56M |
| EPS (ttm) | 32.29 |
| PE Ratio | 28.09 |
| Forward PE | 22.36 |
| Dividend | 11.00 (1.21%) |
| Ex-Dividend Date | Jul 29, 2025 |
| Volume | 42,102 |
| Average Volume | 375,203 |
| Open | 905.30 |
| Previous Close | 905.35 |
| Day's Range | 902.20 - 913.80 |
| 52-Week Range | 725.20 - 1,123.95 |
| Beta | 0.43 |
| RSI | 46.79 |
| Earnings Date | Nov 4, 2025 |
About Alembic Pharmaceuticals
Alembic Pharmaceuticals Limited, an integrated pharmaceutical company, develops, manufactures, markets, and sells pharmaceutical products in India and internationally. The company provides products in various therapeutic areas, such as cardiology, orthopaedics, anti-diabetic, ophthalmology, gynaecology, nephrology, gastrology, urology, dermatology, anti-infective, cold and cough, and animal health; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspe... [Read more]
Financial Performance
In 2024, Alembic Pharmaceuticals's revenue was 66.72 billion, an increase of 7.12% compared to the previous year's 62.29 billion. Earnings were 5.83 billion, a decrease of -5.26%.
Financial StatementsNews
Alembic Pharma shares rise over 2% after USFDA nod for Diltiazem Hydrochloride Tablets
Alembic Pharmaceuticals’ stock inched over 2% higher after the company announced that it has secured final approval from the US...
Alembic Pharma gets USFDA final nod for Diltiazem Hydrochloride Tablets
Alembic Pharmaceuticals has received final approval from the USFDA for its Abbreviated New Drug Application for Diltiazem Hydrochloride Tablets USP...
Alembic Pharma secures final USFDA approval for Dexlansoprazole DR capsules
Alembic Pharmaceuticals announced today that it has secured final approval from the US Food & Drug Administration (USFDA) for its...
Alembic Pharmaceuticals receives USFDA final approval for Dasatinib Tablets across six strengths
Alembic Pharmaceuticals Limited announced that it has received final approval from the US Food & Drug Administration (USFDA) for its...
Q2 2026 Alembic Pharmaceuticals Ltd Earnings Call Transcript
Q2 2026 Alembic Pharmaceuticals Ltd Earnings Call Transcript
Alembic Pharma shares rally sharply over 6% as Q2 net profit jumps 21% YoY to Rs 185 crore, revenue up 16%
Alembic Pharmaceuticals Ltd shares surged more than 6% today after the company reported impressive financial results for the second quarter...
Alembic Pharmaceuticals gets USFDA final approval for Ticagrelor Tablets 60 mg; targets $236 million market
Alembic Pharmaceuticals Limited announced that it has received final approval from the US Food & Drug Administration (USFDA) for its...
Alembic Pharma receives USFDA final approval for Phytonadione Injectable Emulsion USP
Alembic Pharmaceuticals Limited has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Phytonadione Injectable Emulsion USP, 1 m...
Alembic Pharma gains as USFDA approves Macitentan tablets for pulmonary arterial hypertension
Shares of Alembic Pharmaceuticals Ltd were in focus on Tuesday, August 19, after the company announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Macite...
Alembic Pharma shares jump over 2% as USFDA approves Tretinoin Cream USP
Shares of Alembic Pharmaceuticals gained over 2% on Monday, August 19, after the company announced that it has received final approval from the US Food and Drug Administration (USFDA) for its Abbrevia...
Top stocks to watch today, August 18: JK Cement, Swiggy, KEC International, Alembic Pharmaceuticals, Glenmark, auto stocks and more
Markets will track sector-specific developments and company announcements on Monday, August 18. Key updates span GST rationalisation measures, capex plans, earnings, and trade duty recommendations. Po...
Stocks to watch today, August 18: Alembic Pharma, EMS, JK Cement, Star Cement, HDFC Bank, Vodafone Idea, Inox Wind and more
Indian markets are expected to see active stock-specific movements on Monday, August 18, as several companies announced fresh approvals, expansions, contract wins, earnings, and corporate actions. Her...
Alembic Pharma share: Antique maintains buy, raises target to Rs 1,275 on US growth outlook
Antique Broking has maintained a ‘Buy’ rating on Alembic Pharmaceuticals, raising its target price to ₹1,275 from ₹1,154, citing strong growth momentum in the US business and stable domestic execution...
Alembic Pharma gets USFDA nod for Carbamazepine Extended-Release Tablets
Alembic Pharmaceuticals Limited has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Carbamazepine Extended-Release Tablets US...
Alembic Pharma acquires UK-based Utility Therapeutics for $12 million to expand US presence
Alembic Pharmaceuticals Inc., the wholly owned US subsidiary of Alembic Pharmaceuticals Limited, has announced the acquisition of UK-based Utility Therapeutics Ltd. This strategic move marks Alembic’s...
Alembic Pharma share jump 3% after company gets US FDA approval for Doxorubicin Hydrochloride Injection
Shares of Alembic Pharmaceuticals rose nearly 3% in Monday morning trade after the company announced that it has received final approval from the US Food & Drug Administration (USFDA) for its generic ...
Alembic Pharma receives EIR from USFDA for Karakhadi API-III facility
Alembic Pharmaceuticals has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its API-III manufacturing facility located in Karakhadi, ...
Pharma stocks in focus as Trump announces tariffs on sector ‘soon’
Indian pharmaceutical stocks are in focus today after U.S. President Donald Trump announced that pharma tariffs are coming very soon. According to industry data, companies with the highest U.S. revenu...
Alembic Pharma shares dip over 2% after USFDA issues 4 observations for Panelav facility
Shares of Alembic Pharmaceuticals fell over 2% on Monday following news that the United States Food and Drug Administration (USFDA) issued four observations after inspecting the company’s API-I & II f...
Alembic Pharmaceuticals shares in focus after USFDA nod for cancer drug Bosutinib
Shares of Alembic Pharmaceuticals may be in focus after the company announced that it has received final approval from the US Food & Drug Administration (USFDA) for its generic Bosutinib Tablets in 10...
Alembic Pharmaceuticals gets USFDA final approval for Amlodipine and Atorvastatin Tablets
Alembic Pharmaceuticals Limited has received final approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Amlodipine and Atorvastatin Tablets U...
Alembic Pharma gets USFDA nod for Rivaroxaban tablets across four strengths; to launch 2.5 mg in Q1 FY26
Alembic Pharmaceuticals Limited announced on May 15 that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Rivaroxaban T...
Alembic Pharma Q4 profit falls 12%, revenue rises 17%
Alembic Pharmaceuticals experienced a 12.1% dip in Q4 net profit, reaching Rs 156.63 crore, despite a 16.7% surge in revenue to Rs 1,769.64 crore. While India formulations and US revenue showed growth...
Alembic Pharmaceuticals shares drop 2% as Q4 net profit falls 11.9% YoY to Rs 156.89 crore
Alembic Pharmaceuticals saw a dip of over 2% in its shares following the announcement of Q4FY25 results. As of 2:08 PM, the shares were trading 1.94% down at Rs 887.85. Despite this, the company repor...
Alembic Pharmaceuticals Q4 Results: Revenue rises 16.7% YoY to ₹1,769 crore, Net profit down 11.96% YoY
Alembic Pharmaceuticals Ltd announced its financial results for the fourth quarter of FY25, reporting a mixed set of numbers. The company posted a net profit of ₹157 crore, down 11.8% year-on-year (Yo...